PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy
Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-30
Target enrollment:
Participant gender:
Summary
To evaluate whether percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) combined with guideline-directed medical therapy (GDMT), compared to GDMT alone, reduces the time to first occurrence of major adverse cardiovascular events (MACE) through 12 months in patients with ischemic cardiomyopathy and a left-ventricular ejection fraction (LVEF) 40%. MACE is a composite of cardiovascular \[CV\] death, spontaneous myocardial infarction (MI), any unplanned revascularization, heart failure (HF)-related rehospitalization, heart transplantation, requirement of device implantation (e.g., valvular treatment, pacemaker, or left ventricular assist device \[LVAD\]), or requirement of intravenous medications due to worsening heart failure in outpatients.
Phase:
NA
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University